Irritable Bowel Syndrome (IBS) Completed Phase 3 Trials for Eluxadoline (DB09272)

Also known as: Irritable Bowel Disease / IBS (Irritable Bowel Syndrome) / IBS / IBS - Irritable Bowel Syndrome / Irritable Bowel / Colitis, Mucous / Irritable Colon / Colon, Irritable / Irritable Bowel Syndrome(IBS) / Irritable Bowel Syndrome / Mucous colitis / Colitis mucous / Irritable bowel syndrome NOS / Colon spastic / Spastic colon / Irritable colon syndrome / [X]Psychogenic IBS / Functional bowel syndrome

IndicationStatusPhase
DBCOND0030069 (Irritable Bowel Syndrome (IBS))Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01553591Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)Treatment
NCT01553747Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)Treatment